Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSE-UM
2024-515032-76-00Phase 2Completed
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Nov 2021
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AloCelyvir in uveal melanoma (UM), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Objective response rate (ORR) per RECIST 1.1. Started Nov 2021; status: completed.
02
Drugs
AloCelyvir
03
Conditions
uveal melanoma (UM)
Beyond the preview
Go deeper on 2024-515032-76-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515032-76-00.